capacity for anti-AChEs, however, these transgenic mice also resisted muscarinic, nicotinic and serotonergic agonists, indicating that secondary pharmacological changes had occurred. The transgenic mice also developed progressive learning and memory impairments, although their locomotor activities and open-field behaviour remained similar to those of matched control mice. By six months of age, transgenic mice lost their ability to respond to training in a spatial learning water maze test, whereas they performed normally in this test at the age of four weeks. This animal model is therefore suitable for investigating the transcriptional changes associated with cognitive deterioration and for testing drugs that may attenuate progressive damage.
Conclusion:
We conclude that upsetting cholinergic balance may by itself cause progressive memory decline in mammals, suggesting that congenital and/or acquired changes in this vulnerable balance may contribute to the physiopathology of Alzheimer's disease.
Current Biology 1995, 5:1063-1071

Background
Progressive deterioration of memory and learning is a characteristic manifestation of Alzheimer's disease [1] . The molecular mechanisms that underlie this phenomenon are still obscure, as the vast majority (> 90 %) of Alzheimer's disease cases originate sporadically -presumably as a result of multigenic contributions combined with environmental causes [2] . There is therefore a need to search for potential reasons to explain the progressive cognitive decline in Alzheimer's disease.
At the neuropathological level, the neuritic plaques and neurofibrillary tangles which are defining features of this disease are particularly concentrated in brain regions where cholinergic circuits operate [3] . Moreover, the progression of disease symptoms is primarily associated with structural changes in cholinergic synapses [4] , the loss of particular acetylcholine (ACh) receptor subtypes [5] , the death of ACh-producing neurons [6] and the consequent damage to cholinergic neurotransmission [7] . These factors result in a relative excess of the AChhydrolyzing enzyme, acetylcholinesterase (AChE). This spatio-temporal correlation led to the cholinergic theory of Alzheimer's disease [7] and promoted the development of cholinergic therapies [8] .
The first of the cholinergic drugs to be approved for clinical use is tacrine (tetrahydroaminoacridine, THA, Cognex®), an AChE inhibitor which temporarily attenuates the worsening of certain clinical symptoms in patients at the early stages of Alzheimer's disease [8] . The concept behind the use of tacrine is to restore the cholinergic balance, at least for a while, by elevating ACh levels and augmenting the function of the remaining ACh receptors [9] . That tacrine administration has some therapeutic value emphasizes the importance of balanced cholinergic neurotransmission for satisfactory steady-state cognitive function. However, whether imbalanced cholinergic neurotransmission can, by itself, contribute to the progressive decline in Alzheimer's disease has not been addressed.
To examine the consequences of synaptic cholinergic imbalance in vivo, we have recently expressed human AChE in transiently transgenic embryos of Xenopus laevis frogs [10] . The recombinant human enzyme accumulated in neuromuscular junctions and altered their structural features [11] . Moreover, transgenic expression of the mouse © Current Biology 1995, Vol 5 No 9 *The first two authors contributed equally to this research. Correspondence to: Hermona Soreq. E-mail address: soreq@vms.huji.ac.il muscle nicotinic ACh receptor induced similar structural changes at Xenopus neuromuscular junctions, enlarging their post-synaptic length and deepening their synaptic cleft [11] . These alterations resembled those reported for cholinergic brain synapses in patients at the early stages of Alzheimer's disease [4] , suggesting that these changes could also be caused by imbalanced cholinergic neurotransmission. This, in turn, initiated our interest in creating-transgenic mice with congenital AChE overexpression and examining cognitive function in such animals.
The construction of our transgenic mice was conceptually different from other recent models designed to recreate the neuropathological features of Alzheimer's disease. Transgenic mice expressing normal or mutant forms of the 3-amyloid protein died prematurely [12] or developed amyloid plaques rich in 13-amyloid peptides [13] . This shed new light on the histopathological changes that are characteristic of Alzheimer's disease, particularly in carriers of 13-amyloid mutations, but not on the relevant mental deficiencies. The elimination of several key brain proteins by homologous recombination (gene knockout) caused no histopathological changes, but damaged spatial learning [14] [15] [16] or avoidance learning [17] . However, neither the -amyloid transgenic mice nor any of these knockout mice were reported to display the neurochemical changes particular to Alzheimer's disease, one of which is cholinergic imbalance. Furthermore, none of the reported cognitive changes appeared to involve progressive deterioration.
In contrast with the above studies, our efforts were devoted to creating a subtle change in the normal balance of cholinergic neurotransmission within the mammalian brain, mimicking conditions that might exist in patients with no hereditary tendency for Alzheimer's disease. We further limited this change to those cell types in which it naturally takes place, and studied its neurochemical, physiopathological and cognitive consequences in an age-dependent manner. Our findings demonstrate that AChE-overexpressing mice with inheritable cholinergic imbalance undergo selective progressive decline in their capacity for spatial learning and memory, and indicate the usefulness of these mice for exploring the detailed molecular mechanisms that underlie cognitive deterioration in Alzheimer's disease.
Both promoters were shown previously to direct human AChE accumulation in Xenopus neuromuscular junctions [10, 11] , although the CMV promoter was approximately ten-fold more efficient in its capacity to direct production of the AChE protein in Xenopus [10] .
We carried out parallel experiments with both constructs to produce transgenic mice. In the first experiment, we microinjected CMV-ACHE DNA into 70 mouse eggs, but obtained only one viable founder mouse carrying the CMV-ACHE transgene. However, the transgenic DNA was not expressed in the progeny of that mouse. In the second experiment, 40 microinjections of Hp-ACHE DNA yielded three viable pedigrees with 2, 10 and 15 copies of the transgene, respectively. Of these, no enzyme production was observed in the two pedigrees with higher copy numbers of the transgene, but AChE was expressed in the pedigree with two copies of the Hp-ACHE DNA.
The rate of success in obtaining viable AChE-transgenic mice was considerably lower than we have observed previously with other microinjected DNAs [19, 20] , suggesting that AChE overexpression was compatible with life only at low levels. Seven generations of transgenic mice with unmodified Hp-ACHE DNA were thereafter raised from the successful pedigree, and all of them presented grossly normal development, activity and behaviour.
Transgenic Hp-ACHE expression is limited to neurons of the central nervous system Reverse transcription and quantitative polymerase chain reaction (PCR) amplification [20] revealed both human and mouse ACHE mRNA transcripts in dissected brain regions of the apparently homozygous transgenic mice from the fifth and subsequent generations (Fig. 1) . Host ACHE mRNA levels and alternative splicing patterns remained apparently unchanged [21] . Bone marrow and adrenal glands expressed only mouse ACHE mRNAs,
Results
Low-level AChE overexpression is compatible with life
To produce transgenic mice overexpressing AChE, we used two DNA constructs that included the ACHE coding sequence for the brain and muscle form of human AChE [10] . In the first construct, this gene was preceded by the potent ubiquitous promoter from cytomegalovirus (CMV-ACHE construct) [18] . In the second construct, this gene was preceded by a 596 base-pair fragment from the authentic promoter of the human ACHE gene, followed by its first intron (Hp-ACHE construct) [10] . with apparently unmodified concentrations of the principal alternative products. Although the Hp-ACHE promoter includes several MyoD-binding elements [10] , the transgene was not expressed in muscle.
To locate human Hp-ACHE mRNA transcripts in specific mouse brain cell types, we performed in situ hybridization experiments. Labelling was observed in essentially similar brain neurons to those observed in other mammals [22, 23] ; these included cell bodies in the basal forebrain, brainstem and cortex of the transgenic mice. Cholinoceptive hippocampal neurons were intensively labelled, especially in the CA1-CA2 region (Fig. 2) . Thus, expression of the Hp-ACHE transgene was apparently confined to neurons of the host central nervous system (CNS) that normally express the mouse ACHE gene.
Normally processed transgenic AChE accumulates in cholinergic brain regions
AChE from the brains of control and transgenic mice displayed similar sedimentation profiles in sucrose gradient centrifugation, demonstrating unmodified assembly into multimeric enzyme forms (Fig. 3 ). Up to 50 % of the active enzyme in basal forebrain, but none in bone marrow, interacted with monoclonal antibodies specific to human AChE ( Fig. 3 and Table 1 ) [24] . Catalytic activity measurements in tissue homogenates revealed a 100 % increase over control levels in the detergent-extractable amphiphilic AChE fraction from basal forebrain, and more limited increments in cortex, brainstem, cerebellum and spinal cord extracts (Table 1 ). There were no age-dependent changes in this pattern and no differences in the cell-type composition of the bone marrows of transgenic and control mice. Gel electrophoresis followed by chemical staining for enzyme activity [24] revealed similar migration patterns for AChE fromthe brains of transgenic and control mice, indicating comparable glycosylation patterns. Intensified cytochemical staining of AChE activity was observed in brain sections from transgenic mice in all of the areas that stain for AChE activity in normal mice [25] . Staining was particularly intense in the neo-striatum and pallidum (Fig. 4a,b) as well as in the hippocampus (Fig. 4c,d) ; the latter two areas are associated with learning and memory [26, 27] . Moreover, depositions of the electron-dense product of AChE-cytochemical staining were more conspicuous within synapse-forming dendrites in the anterior hypothalamus from transgenic mice than in control brain sections (Fig. 4e,f and Table 2 ). However, synapses interacting with these stained dendrites were of similar lengths in transgenic mice and in controls ( Table 2 ), demonstrating that, unlike the situation in Xenopus laevis neuromuscular junctions [11, 24] , AChE overexpression in the mouse brain did not modify the post-synaptic length of (at least part of) the cholinergic synapses. In addition, there was no indication of neurofibrillary tangles or amyloid plaques in the analyzed brain sections from mice up to six months of age.
Transgenic AChE selectively alters hypothermic drug responses
To investigate the physiological effects of overexpressing transgenic AChE, and because cholinergic synapses in the anterior hypothalamus (where we noted AChE overexpression) are known to be involved in thermoregulation [28] , we examined the responses of transgenic mice to drugs causing hypothermia. The potent AChE inhibitor diethyl p-nitrophenyl phosphate (paraoxon) is the toxic metabolite of the agricultural insecticide parathion; both young (4-5 weeks) and adult (5-7 months) transgenic mice were considerably more resistant to paraoxoninduced hypothermia than non-transgenic controls (Fig.  5a,b) . The transgenic mice were almost totally resistant to a low paraoxon dose (0.25 mg kgl, Fig. 5a ). With higher doses, they displayed limited reduction in body temperature and shorter duration of response than controls (Fig.  5b) . Most importantly, transgenic mice exposed to a 1 mg kg -1 dose of paraoxon retained apparently normal physical activity, whereas control mice experienced myoclonia and muscle stiffening, symptoms characteristic of cholinergic over-stimulation. In addition to their improved capacity for scavenging paraoxon, the transgenic mice also displayed resistance to the hypothermic effects of the muscarinic agonist oxotremorine (Fig. 5c) , to the less potent effect of nicotine (Fig. 5d) , and to the serotonergic agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) (Fig. 5e ), but not to the a 2 -adrenergic agonist clonidine (Fig. 5f) . However, the thermal response to cold exposure remained unchanged in both transgenic and cntrol mice: after 60 minutes of exposure to 5 C, the body temperature of all mice had decreased to 35.5 C, indicating that no changes had occurred in their peripherally induced control over body temperature (data not shown).
Transgenic AChE induces an age-dependent decline in spatial learning capacity To examine their cognitive functioning, transgenic and control mice were subjected to several behavioural tests. At the ages of one, two-three and five-seven months, transgenic mice retained normal locomotor and explorative behaviour, covering the same space and distance in an open field as sex-matched groups of non-transgenic control mice. The open field anxiety of the mice also remained similar, as evaluated in the frequency of defecation incidents and grooming behaviour (Table 3) .
Conspicuous behavioural differences between the transgenic and control mice were observed, however, in two versions of the Morris water maze [29] . In the hidden platform version of this test, mice are expected to use long-distance cues to orient themselves, to find a platform submerged under opaque water and to escape a swimming task [29] . The performance of the transgenic mice was apparently normal in this test at the young age of four weeks -they needed a similar number of training sessions as compared to control mice in order to reach the platform within a significantly shorter time (defined as the escape latency) than untrained mice ( Fig. 6a and Table 3 ). At the age of two or three months, transgenic mice needed eight more training sessions than control mice to improve their performance; the variation between animals also increased, and their shortest escape latency was significantly longer than that of control mice of the same age ( Fig. 6b and I ' r in this test through training, such that their escape latency remained the same as that of untrained mice ( Fig. 6c and Table 3 ).
This pattern of deterioration was not caused by locomotor deficiencies, as was clear when the two groups of mice were compared in the open field test (see above). It could, therefore, reflect changes in memory. Alternatively, or in addition, changes in the acquisition of learning could be involved, which might be affected by motivational factors. It should be noted that the progressive behavioural decline of these transgenic mice was more pronounced than that observed in mice with targetted mutations in the glutamate receptor 1 [14] , the kinase Fyn [15] or calcium calmoduline kinase II [16] , suggesting a more substantial perturbation than in any of these cases.
A different, age-independent defect was observed in the visible platform version of the Morris water maze, in which mice are trained to escape the swimming task by using short-distance cues to climb on a visible platform decorated by a flag and a paper cone [29] . Interestingly, the transgenic mice could not improve their performance in this test through training, regardless of their age (Table 3) , perhaps due to early-onset difficulties in short-distance vision or because of abnormal avoidance behaviour. In either case, the early occurrence of this defect at the age of four weeks, when the hidden platform test was still correctly performed by the transgenic mice, demonstrates that the defects in the visual and the hidden platform test were unrelated.
Discussion
Using the authentic promoter from the human ACHE gene in conjunction with the AChE-coding sequence, we created transgenic mice expressing human AChE in CNS neurons. The levels of overexpression were apparently sufficiently low to be compatible with life. The transgenic enzyme was processed normally and was detected preferentially in brain areas that normally express AChE, where it affected the responses of the transgenic animals to drugs causing hypothermia. Most importantly, there was a rapid decline in the spatial learning capacities of these transgenic animals, initiated in early adulthood and becoming progressively more severe, supporting the notion that subtle cholinergic imbalance can cause progressive learning deficiencies in mammals.
Our failure to obtain viable mice with high levels of AChE overexpression may imply that both the Hp-ACHE promoter, with its limited efficacy, and the low copy numbers of the transgene were important in allowing survival of the ACHE-transgenic mice. The expression pattern of the transgene excluded peripheral organs where the ACHE gene is normally expressed [30] [31] [32] ; in particular, there was no expression in muscle, although MyoD-binding elements are included in the Hp-ACHE promoter. The restriction of expression to CNS neurons may occur because the promoter is incomplete, missing necessary enhancer elements. Alternatively, silencing elements in the promoter, similar to those reported in upstream sequences of the choline acetyltransferase gene [33] , could prevent expression of this transgene in its normal target tissues. Finally, the insertion site within the host genome may affect expression. Additional studies will be required to distinguish between these possibilities.
The limited neuronal expression and low copy number of the transgene ensured that it could only cause a subtle cholinergic imbalance. The transgenic protein was processed and assembled normally, presumably due to the extremely high homology (95 %) between the human and the mouse enzymes [30] [31] [32] . It therefore accumulated in all of the relevant sites, with its highest excess Cognitive damage in AChE transgenic mice Beeri et al. levels being found in the basal forebrain -the region most vulnerable to neuronal loss in Alzheimer's disease [1] . Interestingly, cholinergic synapses within the brains of the transgenic mice retained their normal length, unlike neuromuscular junctions from AChE-overexpressing Xenopus tadpoles. However, the Xenopus synapses also accumulated up to ten-fold more AChE [11, 24] ; in contrast, enzyme excess was limited to two-fold in the mouse synapses analyzed, perhaps reflecting an upper limit compatible with survival in mammals. The question of whether cholinergic imbalance can cause progressive structural changes to other particular types of cholinergic synapses in the mammalian brain must await further examination.
The resistance of transgenic mice to the induction of hypothermia by different agents demonstrated that the functioning of cholinergic synapses was modified by the overexpression of human AChE. Resistance to paraoxon was to be expected, as the amount of its target protein, AChE, was significantly increased in the brains of these mice. However, the resistance to muscarinic, nicotinic and serotonergic agonists reflected secondary changes affecting both cholinergic and serotonergic synapses, or perhaps only cholinergic ones -a recent report demonstrates that 8-OH-DPAT affects nicotinic receptors directly [34] . These changes were caused, either directly or indirectly, by the transgenic enzyme. However, no general alterations occurred in the network of neurons controlling thermoregulation, as the transgenic mice retained normal responses to noradrenergic agents and to cold exposure. This suggests a loss of specific synapses and/or receptor desensitization as possible causes, and indicates the use of cholinergic and serotonergic agonists for the early diagnosis of imbalanced cholinergic neurotransmission in human patients.
From their young adulthood onward, and also at a time when their spatial learning performance with a hidden platform was indistinguishable from that of controls, our transgenic mice failed to respond to short-distance visible cues. This could reflect a particular avoidance behaviour or could be due to the inability of these mice to focus their eyesight on a nearby target. The latter possibility is reminiscent of the differential response of Alzheimer's disease patients to tropicamide [35] . It is possible that autonomic control over pupil constriction and eyesight-focusing muscles requires precisely balanced cholinergic neurotransmission. It will be intriguing to examine whether Alzheimer's disease patients have more difficulties in focusing on nearby targets than unaffected, similarly-aged patients.
Of particular interest are the gradual spatial memory deficits displayed by the AChE-overexpressing transgenic mice in the hidden platform water maze, as opposed to their normal open field behaviour. The onset of these impairments in early adulthood suggests that the cholinergic balance essential for spatial memory can be sustained in younger transgenic mice, perhaps by a feedback mechanism that adjusts other key elements in cholinergic synapses. This intricate process resembles the increase in xo-bungarotoxin binding levels in Xenopus embryos that overexpress AChE, and the reciprocal AChE accumulation in neuromuscular junctions of tadpoles expressing the mouse nicotinic ACh receptor [11] . Further to these observations, we now learn that, in mammals, this adjustment of the cholinergic balance can only be maintained for a limited time.
Several mechanisms of various levels have been implicated in the control of CNS cholinergic balance. Various ACh receptor genes have been shown to share common promoter elements [36, 37] , thus ensuring co-regulation by trans-acting factors. Furthermore, a single cis-acting promoter controls the production of both the vesicular ACh transporter and choline acetyltransferase [38, 39] . A gradual failure to maintain either or both of these mechanisms, or others, may be involved in the progressive changes observed in our mice. The appearance of memory perturbation in the early stages of Alzheimer's disease may similarly signal the onset of failure to sustain cholinergic balance at the precise levels required for memory. The increase in brain AChE activity under stress [40] and the heterogeneous genomic origin of Alzheimer's disease in the vast majority of patients [2] may indicate that failure to maintain cholinergic balance can be due to variable causes.
The possibility exists that the overexpression of AChE may have effects that relate to the potential non-catalytic function(s) of this intriguing protein. Although the phenotypic differences observed in the transgenic mice are most probably correlated with acetylcholine hydrolysis, further experiments should be performed to explore any correlation with the potential functions of AChE in cellto-cell interactions [41, 42] . Indeed, evidence accumulated from patients suggests that AChE per se is closely linked to Alzheimer's disease: in patients, the brain ratio between AChE monomers and tetramers is significantly modified [43] ; in the adrenal gland, selective AChE depletion has been observed [44] ; and in the cerebrospinal fluid, a catalytically active AChE form with an anomalous isoelectric point has been detected [45] . These observations indicate that a functional excess of AChE might, independent of the catalytic site, be subsequently exerting new and possibly dangerous roles.
In either case, the gradual impairment of learning and memory due to AChE overexpression is consistent with the temporary partial improvement seen when antiAChE drugs are administered to Alzheimer's disease patients [8, 9] . Moreover, preliminary differential PCR displays [46, 47] of mRNA from dissected brain regions of our transgenic mice have revealed age-dependent transcriptional changes, which await characterization. This approach may unravel the target genes being affected by the transgene. Testing the effects of drug treatments on the progressive transcriptional changes that occur in the brain of these mice might thereafter lead to RESEARCH PAPER 1069 the development of novel strategies for prophylactic treatment of neurodegenerative disorders associated with cholinergic imbalance.
Finally, although AChE-overexpressing mice provide a model for behavioural, physiological and molecular aspects of cholinergic imbalance in mammals, they also demonstrate a dissociation between this imbalance and the P-amyloid deposits that occur in Alzheimer's disease. The possibility remains that cholinergic neurons are particularly sensitive to the neurotoxicity attributed to the P-amyloid peptides [12, 13] , in which case 3-amyloid transgenic mice should develop cholinergic deficiencies with time. Alternatively, or in addition, cholinergic imbalance Ipay lead to abnormal -amyloid expression, in which case the AChE transgenic mice should develop 13-amyloid deposits with time. A third possibility is that the linkage between the pathophysiological and the cognitive manifestations in Alzheimer's disease is unique to Homo sapiens.
Conclusions
Expression of human AChE in CNS neurons of transgenic mice creates impairments in spatial learning and memory which appear shortly after early adulthood and become progressively more severe. From early adulthood, these mice also show a marked, yet stable, decrease in performance in a visible water maze test. The openfield behaviour of the transgenic animals remains normal, although their responses to hypothermia-inducing drugs are decreased. These findings suggest that subtle alterations in cholinergic balance may cause physiologically observable changes and contribute to memory deterioration in at least some patients with sporadic Alzheimer's disease.
Materials and methods
Production of transgenic mice DNA constructs were injected into fertilized eggs of FZB/N mice as described [19, 20] . PCR amplification and Southern blot hybridization of tail DNA samples verified integration of variable copy numbers of the transgene into the genomes of founder mice and their progeny.
RNA extraction and PCR amplification
These were performed as detailed [20] , except that the annealing temperature was 69 C. Species-specific PCR primers were designed for human ACHE mRNA at nucleotides 1522(+) and 1797(-) in exons 3 and 4 [24] , and for mouse at nucleotides 375(+) and 1160(-) in exons 2 and 3 [21] . Resultant PCR products (276 and 786 bp, respectively) were electrophoresed on agarose gels.
In situ hybridization Wholemount in situ hybridizations were performed at 65 C on 50 pIm-thick, 4 % paraformaldehyde/1 % glutaraldehyde-fixed sections of transgenic and control brains with digoxigeninlabelled complementary human ACHE cRNA. Detection was with alkaline-phosphatase-conjugated anti-digoxigenin antibody (Boehringer/Mannheim).
AChE activity measurements
Acetylthiocholine hydrolysis levels were determined, following sucrose gradient centrifugation of tissue homogenates, prior to or following adhesion to human-selective anti-AChE monoclonal antibodies, essentially as detailed [24, 32] .
AChE cytochemical staining
Whole-mount cytochemical staining of AChE activity was performed on 50 lim-thick, paraformaldehyde-glutaraldehydefixed sections of brains as detailed [24] , except that incubation was for 2 h. Electron microscopy was thereafter performed on 80 nm sections of paraformaldehyde-glutaraldehyde-fixed brain [24] . Control experiments with no acetylthiocholine verified that these electron-dense deposits were indeed reaction products of in situ AChE catalysis.
Hypothermic response measurements
Core body temperature was measured rectally in mice, using a thermocoupled element of 1 mm diameter and 10 mm length, at the noted times after intraperitoneal injections of paraoxon, oxotremorine, nicotine, tetralin (8-OH-DPAT) or clonidine.
Morris water maze tests
Mice were tested in a 60 x 60 x 15 cm water maze filled with 1.5 mg 1-1 powdered milk, with a submerged hidden platform in a fixed location 1 cm below water level. Four trials of up to 2 min were performed per day for four days, each initiated randomly in a different comer of the maze. For the visual platform test, the water level was lowered by 2 cm, and a 10 cm high striped flag and a 7 cm high black cone were positioned on top of the now visible platform. Mean escape latencies per day (four sessions) were calculated for transgenic and sex-and agematched controls, and statistically significant reductions of latencies were searched for as compared with the first day values in each section (one-way ANOVA, followed by Neuman Keuls test).
Open field test
Mice were placed in one corner of a 60 x 60 cm Plexiglass box with 30 cm high walls and the floor divided into 144 squares of 5 x 5 cm each. Using these squares, the motion path of the animals was manually traced for 5 min, which enabled measurements of walking distance and explored area. Grooming behaviour and incidence of defecations were also noted.
